A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy

Cancer Prevention Research

Volumn 6, Issue 10, 2013, Pages 1120-1127

  Freedland, Stephen J ^a,b   Carducci, Michael ^d,e   Kroeger, Nils ^f,g   Partin, Alan ^d,e   Rao, Jian Yu ^f   Jin, Yusheng ^f   Kerkoutian, Susan ^f   Wu, Hong ^f   Li, Yunfeng ^f   Creel, Patricia ^c   Mundy, Kelly ^c   Gurganus, Robin ^e   Fedor, Helen ^e   King, Serina A ^d   Zhang, Yanjun ^f   Heber, David ^f   Pantuck, Allan J ^f  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DRUG METABOLITE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PHOSPHOTRANSFERASE; POMEGRANATE EXTRACT; PROSTATE SPECIFIC ANTIGEN; PS6 KINASE; TUMOR MARKER; UNCLASSIFIED DRUG; UROLITHIN A;

ADULT; ARTICLE; BIOACCUMULATION; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PILL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; CHROMATOGRAPHY, LIQUID; COMBINED MODALITY THERAPY; COUMARINS; DEOXYGUANOSINE; DOUBLE-BLIND METHOD; HUMANS; KI-67 ANTIGEN; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOADJUVANT THERAPY; NF-KAPPA B; OXIDATIVE STRESS; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PUNICACEAE; RIBOSOMAL PROTEIN S6 KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84887986296     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0423     Document Type: Article

References (28)

1. Bishop FL, Rea A, Lewith H, Chan YK, Saville J, Prescott P, et al. Complementary medicine use by men with prostate cancer: a systematic review of prevalence studies. Prostate Cancer Prostatic Dis 2011;14:1-13.
2. Bell C, Hawthorne S. Ellagic acid, pomegranate and prostate cancer - a mini review. J Pharm Pharmacol 2008;60:139-44. (Pubitemid 351211828)
3. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, et al. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 2007;55:7732-7. (Pubitemid 47522181)
4. Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ, et al. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res 2010;20:55-62.
5. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 2008;32:475-80. (Pubitemid 351200247)
6. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther 2008;7:2662-71.
7. Adhami VM, Siddiqui IA, Syed DN, Lall RK, Mukhtar H. Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis 2012;33:644-51.
8. Wang L, Alcon A, Yuan H, Ho J, Li QJ, Martins-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol 2011;3:742-54.
9. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12:4018-26. (Pubitemid 44078089)
10. Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013;16:50-5.
11. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004;101:1569-74. (Pubitemid 39318903)
12. Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev 2012;21:155-62.
13. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000;71:1062-76. (Pubitemid 30230552)
14. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Onoda N, et al. Immunohistochemical detection of 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, in human chronic cholecystitis. Histopathology 2002;40:531-5. (Pubitemid 34621811)
15. Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, van Breemen R, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001;93:1872-9. (Pubitemid 34048654)
16. Luo H, Tang L, Tang M, Billam M, Huang T, Yu J, et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006;27:262-8. (Pubitemid 43159878)
17. Johanningsmeier SD, Harris GK. Pomegranate as a functional food and nutraceutical source. Annu Rev Food Sci Technol 2011;2:181-201.
18. Gonzalez-Sarrias A, Gimenez-Bastida JA, Garcia-Conesa MT, Gómez-Sánchez MB, García-Talavera NV, Gil-Izquierdo A, et al. Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol Nutr Food Res 2010;54:311-22.
19. Heber D. Pomegranate Ellagitannins. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton, FL: CRC Press; 2011.
20. Seeram NP, Lee R, Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 2004;348:63-8. (Pubitemid 39209002)
21. Seeram NP, Zhang Y, McKeever R, Henning SM, Lee RP, Suchard MA, et al. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food 2008;11:390-4. (Pubitemid 351948184)
22. Malins DC, Johnson PM, Barker EA, Polissar NL, Wheeler TM, Anderson KM. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci U S A 2003;100:5401-6. (Pubitemid 36542717)
23. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. (Pubitemid 46486616)
24. Kondo S, Toyokuni S, Iwasa Y, Tanaka T, Onodera H, Hiai H, et al. Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic Biol Med 1999;27:401-10. (Pubitemid 29395434)
25. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996;32A:30-8.
26. Wainfan E, Poirier LA. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res 1992;52:2071s-7s.
27. Trzeciak AR, Nyaga SG, Jaruga P, Lohani A, Dizdaroglu M, Evans MK. Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145. Carcinogenesis 2004;25:1359-70. (Pubitemid 39162702)
28. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2′ -deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2009;27:120-39.